Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer

Jill M. Siegfried, Mariya Farooqui, Natalie J. Rothenberger, Sanja Dacic, Laura P. Stabile

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


The estrogen receptor (ER) promotes non-small cell lung cancer (NSCLC) proliferation. Since fibroblast growth factors (FGFs) are known regulators of stem cell markers in ER positive breast cancer, we investigated whether a link between the ER, FGFs, and stem cell markers exists in NSCLC. In lung preneoplasias and adenomas of tobacco carcinogen exposed mice, the anti-estrogen fulvestrant and/or the aromatase inhibitor anastrozole blocked FGF2 and FGF9 secretion, and reduced expression of the stem cell markers SOX2 and nanog. Mice administered β-estradiol during carcinogen exposure showed increased FGF2, FGF9, SOX2, and Nanog expression in airway preneoplasias. In normal FGFR1 copy number NSCLC cell lines, multiple FGFR receptors were expressed and secreted several FGFs. β-estradiol caused enhanced FGF2 release, which was blocked by fulvestrant. Upon co-inhibition of ER and FGFRs using fulvestrant and the pan-FGFR inhibitor AZD4547, phosphorylation of FRS2, the FGFR docking protein, was maximally reduced, and enhanced anti-proliferative effects were observed. Combined AZD4547 and fulvestrant enhanced lung tumor xenograft growth inhibition and decreased Ki67 and stem cell marker expression. To verify a link between ERβ, the predominant ER in NSCLC, and FGFR signaling in patient tumors, mRNA analysis was performed comparing high versus low ERβ expressing tumors. The top differentially expressed genes in high ERβ tumors involved FGF signaling and human embryonic stem cell pluripotency. These results suggest interaction between the ER and FGFR pathways in NSCLC promotes a stem-like state. Combined FGFR and ER inhibition may increase the efficacy of FGFR inhibitors for NSCLC patients lacking FGFR genetic alterations.

Original languageEnglish (US)
Pages (from-to)24063-24076
Number of pages14
Issue number15
StatePublished - 2017

Bibliographical note

Funding Information:
Supported by the SPORE in Lung Cancer grant P50 090440 (JMS/LPS) from the National Cancer Institute and a grant from the V Foundation for Cancer Research (JMS/LPS). This project used the UPCI and MCC Animal Facilities and was supported in part by award P30CA047904 and award P30CA077598.


  • Estrogen
  • FGFR


Dive into the research topics of 'Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this